Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV

SARS-CoV was the cause of the global pandemic in 2003 that infected over 8000 people in 8 months. Vaccines against SARS are still not available. We developed a novel method to produce high levels of a recombinant SARS virus-like particles (VLPs) vaccine containing the SARS spike (S) protein and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ye V., Massare, Michael J., Barnard, Dale L., Kort, Thomas, Nathan, Margret, Wang, Lei, Smith, Gale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165014/
https://www.ncbi.nlm.nih.gov/pubmed/21762752
http://dx.doi.org/10.1016/j.vaccine.2011.06.111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165014/
https://www.ncbi.nlm.nih.gov/pubmed/21762752
http://dx.doi.org/10.1016/j.vaccine.2011.06.111

Ejemplares similares